3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
10
Colorectal Neoplasms
5
Stomach Neoplasms
3
Rhabdomyosarcoma
3
Osteosarcoma
3
Biliary Tract Neoplasms
3
Sarcoma, Ewing
2
Recurrence
2
Rectal Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Small Bowel Adenocarcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Cancer Patients
1
Peritoneal Neoplasms
1
PDAC - Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Nasopharyngeal Carcinoma
1
Metastatic Gastric Adenocarcinoma
1
Metastatic Adenocarcinoma of the Pancreas
1
Malignant Ascites
1
Hepatoblastoma
1
Gastrointestinal Neoplasms
1
Gastroesophageal Junction Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Gemcitabine
33
Cisplatin
28
pembrolizumab
19
durvalumab
17
Oxaliplatin
16
Fluorouracil
16
Leucovorin
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
9
Biopsy
9
lenvatinib
7
Nivolumab
7
Capecitabine
7
Taxes
6
Paclitaxel
6
Irinotecan
6
fludarabine
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
pemigatinib
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
tremelimumab
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
irinotecan sucrosofate
×
1 year
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled